Cowen & Co. analyst Marc Frahm initiated coverage with a Buy rating on X4 Pharmaceuticals Inc (XFOR) today. The company’s shares closed yesterday at $14.16, close to its 52-week low of $6.90.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 1.4% and a 53.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for X4 Pharmaceuticals Inc with a $23.50 average price target, a 66.0% upside from current levels. In a report issued on May 21, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Based on X4 Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.87 million. In comparison, last year the company had a GAAP net loss of $10.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
